The rise in type 2 diabetes has become a significant public health concern in recent years. This form of diabetes happens when the body struggles to use insulin properly.
Insulin is a hormone that helps keep blood sugar levels steady, and when it doesn’t work as it should, blood sugar levels can climb too high. Managing blood sugar is essential for people with type 2 diabetes, and many start with a drug called metformin, which is usually effective as the first line of treatment.
However, for some, metformin alone isn’t enough to control blood sugar, so doctors often add a second medication.
When it comes to adding a second medication, doctors traditionally prescribe one of two common options: sulfonylureas or basal insulin. Both have been used for years to help keep blood sugar levels in check.
But a new study from Northwestern University has highlighted a serious downside to these drugs. Researchers found that sulfonylureas and basal insulin may increase the risk of heart-related problems, such as heart attacks, strokes, heart failure, and even amputations.
This study is the first to directly compare how each of the six major second-line diabetes drugs affects heart health in people with type 2 diabetes.
In their research, scientists discovered that those who took either sulfonylureas or basal insulin had a significantly higher chance of experiencing heart issues compared to those on newer types of diabetes medications called DPP-4 inhibitors.
Specifically, patients taking sulfonylureas had a 36% higher risk of heart-related problems, while those on basal insulin faced double the risk. These findings suggest that older medications like sulfonylureas and basal insulin may carry serious heart risks.
Given these results, the researchers recommend that doctors consider prescribing newer diabetes medications after metformin, such as GLP-1 agonists, SGLT-2 inhibitors, or DPP-4 inhibitors, which have been associated with fewer heart-related issues.
Although these newer medications might be more costly, avoiding hospital visits and treating fewer heart complications could ultimately save patients and healthcare systems money.
These newer drugs not only help regulate blood sugar but could also reduce the risk of severe heart problems, improving the overall quality of life for patients with diabetes.
To conduct the study, the research team used data from 132,737 people with type 2 diabetes who had just started a second medication after metformin.
This observational study drew on real-world patient information, making it different from previous studies, which often focused on comparing one drug to a placebo (an inactive pill).
Although this type of study cannot prove cause and effect, it provides strong evidence linking sulfonylureas and basal insulin to a higher likelihood of heart-related problems.
However, the study also has limitations. It didn’t specifically test whether these older drugs could still be beneficial for some people or how they compared to newer drugs in their ability to control blood sugar.
Despite this, the study’s results raise questions about the safety of these traditional medications.
In fact, a startling statistic from the research reveals that among the millions of people with diabetes in the United States, doctors would only need to prescribe basal insulin to about 37 patients over two years to observe a single cardiovascular event, such as a heart attack or stroke. For sulfonylureas, it would take 103 patients to see one of these events.
This evidence suggests that people with type 2 diabetes should be informed about the potential risks associated with their medications. The findings point toward a shift in how type 2 diabetes could be managed, encouraging doctors to more frequently consider these newer medications that might lower heart risks.
Of course, newer medications tend to be more expensive, but by reducing the risk of serious heart problems, they might help avoid costly medical treatments and improve life quality.
Heart health is crucial, especially for people managing type 2 diabetes. Lowering the risk of heart disease can not only enhance life quality but also save lives.
The study from Northwestern University provides essential insights, urging healthcare providers to rethink their approach to second-line diabetes treatments.
By choosing options like GLP-1 agonists, SGLT-2 inhibitors, or DPP-4 inhibitors, doctors may help prevent heart issues and offer safer treatment alternatives for their patients.
This research, led by Dr. Matthew O’Brien and published in JAMA Network Open, is part of a growing field of studies on how best to treat diabetes with fewer risks.
The findings remind us of the importance of heart health in diabetes care and encourage more informed choices about medication options for people with type 2 diabetes.
If you care about diabetes, please read studies about high vitamin D level linked to lower dementia risk in diabetes, and this eating habit could help reduce risk of type 2 diabetes.
For more information about health, please see recent studies about unhealthy plant-based diets linked to metabolic syndrome, and results showing Paleo diet plus exercise could boost heart health in people with diabetes.
Copyright © 2024 Knowridge Science Report. All rights reserved.
